UMVA has learned that the United States bears a disproportionate burden of the world's pharmaceutical costs, with Americans paying far more for drugs than any other country.
This staggering disparity is largely due to foreign governments' strategic pricing systems, which severely limit what they pay for life-saving medications, effectively shifting the financial burden to the United States.
These foreign pricing systems, UMVA can exclusively reveal, are tantamount to trade distortions that stifle competition and innovation, forcing American patients to foot the bill for the lion's share of global research and development costs.
Countries like Germany, France, and Japan aggressively impose government pricing mandates, mandatory rebates, and strict market controls that drastically cap what they pay for medicines, often well below U.S. market prices.
This puts pharmaceutical manufacturers in a difficult position: either accept the punitive terms or risk being shut out of these critical markets, ultimately leading to the United States shouldering the bulk of the financial burden.
A recent development in Germany exemplifies the accelerating trend of distorted pricing systems, as the government advanced a sweeping cost-containment proposal that would expand mandatory rebates and tighten price-volume rules.
France, Japan, and Switzerland are now pursuing similar approaches, signaling a broader trend across major U.S. trading partners that threatens to further exploit American consumers.
These countries often characterize their pricing systems as domestic healthcare policy, but UMVA has gathered that they amount to non-tariff trade barriers that stifle innovation and unfairly burden U.S. commerce.
The Trump administration has been moving in the right direction, exploring voluntary Most Favored Nation pricing arrangements and considering Section 301 action to address these discriminatory practices.
A Section 301 investigation would establish a critical evidentiary foundation to pursue a fairer distribution of pharmaceutical development costs and signal that the status quo is no longer acceptable.
There is broad public support for action, with a large majority of Americans believing that other countries should pay a fairer share for medicines, reflecting a basic principle that a system in which one country consistently subsidizes global innovation is unsustainable.
It's time for the Trump administration to use the tools available to remedy the balance and help ensure that pharmaceutical innovation continues, protecting America's position as a leader in drug innovation and safeguarding the lives of millions worldwide.
